Literature DB >> 18600839

Production of monoclonal antibody using free-suspended and immobilized hybridoma cells: Effect of serum.

G M Lee1, A Varma, B O Palsson.   

Abstract

The effect of serum on cell growth and monoclonal antibody (MAb) productivity was studied in a repeated fedbatch mode using both free-suspended and immobilized S3H5/gamma2bA2 hybridoma cells. In the suspension culture, serum influenced the cell growth rate but not the specific MAb productivity. The average specific growth rate of the suspension culture in medium containing 10% serum was approximately 0.99 +/- 0.12 day(-1) (+/-standard deviation), while that in medium containing 1% serum was approximately 0.73 +/- 0.12 day(-1). The specific MAb productivity was almost constant at 3.69 +/- 0.57 microg/10(6) cells/day irrespective of serum concentration reached a maximum at ca. 1.8 x 10(6) cells/mL of medium in 10% serum medium, and the cell concentration was gradually reduced to 1%. The specific MAb productivity of the immobilized cells was more than three times higher than that of the free-suspended cells. The amount of serum in the medium did not influence the specific MAb production rate of the immobilized cells. The maintenance of high cell concentration and the enhanced specific MAb productivity of the immobilized cell culture resulted in a higher volumetric MAb productivity. In addition, MAb yield in the immobilized cell culture with medium containing 1% serum was 2.2 mg/mL of serum, which was approximately three times higher than that in the suspension culture.

Year:  1991        PMID: 18600839     DOI: 10.1002/bit.260380804

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  12 in total

1.  Biphasic culture strategy based on hyperosmotic pressure for improved humanized antibody production in Chinese hamster ovary cell culture.

Authors:  Min Soo Kim; No Soo Kim; Yun Hee Sung; Gyun Min Lee
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-06       Impact factor: 2.416

2.  Maximisation of perfusion systems and process comparison with batch-type cultures. Maximisation of perfusion cultures.

Authors:  J B Griffiths; D Looby; A J Racher
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

3.  Changes in monoclonal antibody productivity of recombinant BHK cells immobilized in collagen gel particles.

Authors:  M Yamaguchi; Y Shirai; Y Inouye; M Shoji; M Kamei; S Hashizume; S Shirahata
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

4.  Long-term Continuous Production of Monoclonal Antibody by Hybridoma Cells Immobilized in a Fibrous-Bed Bioreactor.

Authors:  Hui Zhu; Shang-Tian Yang
Journal:  Cytotechnology       Date:  2004-01       Impact factor: 2.058

5.  Effect of hypoosmotic pressure on cell growth and antibody production in recombinant Chinese hamster ovary cell culture.

Authors:  M S Lee; G M Lee
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

6.  Enhanced production of human recombinant proteins from CHO cells grown to high densities in macroporous microcarriers.

Authors:  T Tharmalingam; K Sunley; M Spearman; M Butler
Journal:  Mol Biotechnol       Date:  2011-11       Impact factor: 2.695

7.  Enhanced specific antibody productivity of calcium alginate-entrapped hybridoma is cell line-specific.

Authors:  G M Lee; S J Kim; B O Palsson
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

8.  Metabolic and kinetic studies of hybridomas in exponentially fed-batch cultures using T-flasks.

Authors:  A E Higareda; L D Possani; O T Ramírez
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

9.  Hybridoma culture in polyether sponge with bovine whey.

Authors:  J Capiaumont; C Legrand; B Dousset; F Belleville; P Nabet
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-06       Impact factor: 2.416

10.  Enhancement of recombinant erythropoietin production in CHO cells in an incubator without CO(2) addition.

Authors:  S K Yoon; Y H Ahn; K Han
Journal:  Cytotechnology       Date:  2001-10       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.